Newcastle Health Research Partnership Advanced Therapies seminar | T cell therapy and its use in viral infections and malignancies with Dr Patrick Hanley

NHIP Advanced Therapies seminar | T cell therapy and its use in viral infections and malignancies with Dr Patrick Hanley

We are delighted to welcome Dr Patrick Hanley to deliver our final Advanced Therapies Satellite seminar of 2024. Dr. Hanley is the Chief and Director of the Cellular Therapy Program and an associate professor of pediatrics at Children’s National Hospital and the George Washington University, respectively. He oversees processing for standard of care stem cell transplantation as well as the development, manufacture, quality, and testing of novel cell and gene therapies. Over the past 16 years he has helped to translate more than 600 products on over 25 cell therapy protocols – ranging from mesenchymal stromal cells to cord blood virus-specific T cells and tumor-associated antigen specific T cells – into the clinic.

Dr. Hanley was elected VP-North America of the International Society for Cell and Gene Therapy (ISCT) where he also serves on the board of directors, co-founded and served as the inaugural co-chair of the Early Stage Professionals committee which focuses on workforce development, and is the commissioning editor of the society’s journal, Cytotherapy. Representing ISCT, he serves on the Regenerative Medicine Forum of the National Academies where he co-leads the workforce working group. He also serves on the board of directors of the Foundation for the Accreditation of Cellular Therapy (FACT) and is a FACT representative at the Cell Therapy Liaison Meeting, serving as a thought leader in a forum with the FDA. Dr Hanley also serves as an advisor for a number of cell and gene therapy biotech companies. In his free time he enjoys tweeting with fellow scientists and Bills fans, playing soccer, cycling, cooking, and traveling.

In this seminar, Dr Hanley will discuss the various uses of antigen specific T cells and how they can be used to target a number of viruses such as CMV, EBV, adenovirus, SARS-CoV-2, and more. He will then discuss the evolution of antigen-specific T cells to target malignancies, including leukemia, pediatric solid tumors, and pediatric brain tumors. Finally, he will detail how these strategies have matured from therapies only offered at his own institution to therapies offered throughout the entire United States as part of consortium studies and how this needs further maturation to increase patient access nationwide.

 

Register for this event here.